A composition of at least one cannabinoid in a specific amount, and at least one primary terpene in a specific amount, where a total terpenes to total cannabinoids weight/weight ratio in the composition is from about 0.05 to about 1.0.

This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer therapeutic. In some aspects, the cannabinoid is chosen from i) CBC, CBCA, CBD, CBDA, CBDV, CBDVA, CBG, CBGA, CBL, CBLA, CBN, CBNA, THCV, THCVA, and any combination thereof, and ii) an approximately 1:1 equimolar mixture of CBD:CBDA. In some aspects, the omega fatty acid is chosen from an omega-3 fatty acid (such as ALA, DHA, or EPA), an omega-7 fatty acid, or an omega-9 fatty acid.

The present invention relates to specific types of pharmaceutical formulations and compositions comprising cannabinoids for use in the treatment of various disorders.

A composition of a Cannabis sativa extract comprising cannabinoids in concentrations ranging from 0.500 to 10.000% (w/w), and terpenes in concentrations ranging from 0.005 to 1.000% (w/w). The use of the composition in the prevention and/or treatment of inflammatory diseases is also described. The composition may also be used as a functional food ingredient.

The present invention relates to specific types of pharmaceutical formulations and compositions comprising cannabinoids for use in the treatment of various disorders.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD) wherein the composition is preferably administered in a mucosal form, such as intravaginally.

A nebulizer device for administering aerosol cannabinoid mixtures to a user includes a mouthpiece, a first reservoir, a second reservoir, and a nebulizer device. The nebulizer module is configured to receive a first dosage of the first liquid from the first reservoir and a second dosage of a second liquid from the second reservoir. The nebulizer module is also configured to transform the first liquid into an inhalant and the second liquid into an aerosol that are provided to the user through the mouthpiece. The device further includes a dosage module configured to independently control the delivery of the first liquid and the second liquid to the nebulizer module to set a ratio between the first dosage of the first liquid and the second dosage of the second liquid. The dosage module thereby controls a composition of an aerosol cannabinoid mixture administered to the user.

Traditional methods of hash production are very labor intensive, and do not yield a product that is homogeneous, whether within a unit or across multiple units from a batch. The present disclosure relates to a hash product comprising a cohesive mass of isolated cannabis trichomes and a marker, where the distribution of the marker is substantially homogeneous throughout the product. For example, the detectable marker can be distributed in at least 80 vol.% of the hashish product. Additionally, or alternatively, the hashish product includes a first content of the marker in a core portion thereof and a second content of the marker in a peripheral portion thereof, where the first content and the second content are present in a ratio first content / second content of from 0.85 to 1.15. Such hash product may be consumed by inhalation or ingestion.

Described herein are compositions for topical use comprising active agents to provide pain relief. The compositions comprise a magnesium salt, a cannabinoid and at least one additional topical analgesic agent. Additionally described herein are methods for treating pain comprising administering to a person in need thereof a composition comprising a pharmaceutically effective amount of a cannabinoid, a magnesium salt and at least one of: methyl salicylate, and menthol.